SEC charges Bristol-Myers Squibb over FCPA violations
Bristol-Myers Squibb will pay the US Securities and Exchange Commission (SEC) US$14 million to settle charges that "its joint venture in China made cash payments and provided other benefits to health care providers at state-owned and state-controlled hospitals in exchange for prescription sales".
To read more
Subscribe to Global Investigations Review
Subscribe and start reading now
Global Investigations Review (GIR) is the hub for global coverage of corporate investigations and their aftermath. Keep up to date with significant developments in the corporate investigations world.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10